HPV Associated Disorders Market - Forecasts from 2024 to 2029

The HPV associated disorders market is estimated to grow at a CAGR of 9.65% during the forecast period.

More than 100 viruses make up the human papillomavirus family, 14 of which can lead to cancer. HPV is the reason for almost all occurrences of cervical cancer. In women living in less developed areas, cervical cancer is the second most prevalent kind, with an estimated 6,04,000 new cases and 3342,000 deaths every year. Cervical cancer is six times more common in women living with HIV than in those without the virus, and HIV is thought to be the cause of 5% of cervical cancer occurrences. Furthermore, younger women are disproportionately affected by HIV-related cervical cancer in all parts of the world.

Growing prevalence of cervical cancer

The World Health Organization (WHO) Factsheet states that palliative care is a crucial component of comprehensive cervical cancer control, in addition to primary prevention measures like HPV vaccination, secondary prevention measures like pre-cancerous lesion screening and treatment, and tertiary prevention measures like diagnosis and treatment of invasive cervical cancer. Such health authority rules contribute to the HPV-associated disorders market expansion. Similar to this, the Australian Government has pledged USD 5.8 million to assist the World Health Organization's (WHO) announcement of a worldwide commitment to eradicate cervical cancer in November 2021. The National Cervical Screening Program urges women to have a fast test for HPV, a common virus that nearly invariably leads to cervical cancer, every five years.

Government initiatives for the treatment of HPV Associated Disorders

Government around the globe is focusing on various initiatives for the treatment of HPV-associated disorders. For instance, to meet the 2030 SDGs, the Indonesian government is dedicated to reducing morbidity, mortality, and disability brought on by illnesses that may be prevented by vaccination. The Ministry of Health has made it a priority to improve health services in the nation by expanding and strengthening health services to concentrate more on preventive promotive efforts. One way to achieve this is by adding new vaccines to the national immunisation programme, such as the HPV vaccine. The government is dedicated to creating a more robust and inventive system. Furthermore, the WHO Strategic Advisory Group of Experts on Immunisation (SAGE) met in April 2023 and reviewed the mounting evidence showing single-dose schedules are just as effective as two- or three-dose regimens.

Growing preference for HPV tests

HPV tests outperform other screening techniques, such as pap smears and visual inspection with acetic acid (VIA), allowing for the identification of more people who require treatment, due to the greater quality, patients who obtain a negative HPV test result can frequently wait longer between tests, which is advantageous for both them and the healthcare system. A few HPV tests even provide patients the option to collect their sample with a simple swab, giving women the option to get tested without having a healthcare provider do a pelvic exam. Numerous HPV tests are even performed using the same hardware as COVID-19 PCR and HIV assays, among others, allowing them to be integrated into current laboratory systems. Such technologies can help remove more obstacles to services and make it easier for public health initiatives to reach the aim of 70% screening.

Growing initiatives by healthcare organizations

The list of prequalified tests for human papillomavirus (HPV) now includes a fourth test, according to WHO. While the majority of HPV infections go away on their own, some high-risk varieties can result in cervical cancer. Cervical cancer screening always includes testing for HPV infection. The prequalification (PQ) programme for in vitro diagnostics (IVDs) run by the WHO assesses a variety of tests, including those used to screen for cervical cancer and identify high-risk HPV genotypes. The inclusion of yet another item to the PQ list broadens the selection of high-performance tests that nations may access, especially when governments, UN organisations, or other partners depend on the WHO programme to facilitate their purchase.

Rising demand for HPV vaccinations

Throughout the anticipated period, the demand for HPV vaccinations is anticipated to be the main factor driving the global HPV-associated disorders industry potential due to the rising prevalence of HPV-related disorders. Bivalent, quadrivalent, and nonavalent vaccinations are the kinds of vaccinations available on the market. The three vaccinations are all quite effective at protecting against the 16 and 18 viruses, which represent 70% of cervical cancer cures. The regulatory authorities' acceptance of the new vaccine increases the accessibility of vaccines for immunisation or vaccination, which is projected to hasten HPV-associated disorders market expansion.

Skeletal dysplasia market in the Asia Pacific region is anticipated to grow steadily.

The HPV-associated disorders market in the Asia Pacific is anticipated to be fueled by the presence of major HPV-associated disorders industry players and growth in various initiatives in the region. For instance, in October 2022, on the last day of the 73rd session of the WHO Regional Committee for the Western Pacific, delegates approved frameworks designed to prevent and control cervical cancer, reach the unreached, and advance the best possible mental and physical health for everyone in the region. Over 95% of occurrences of cervical cancer are associated with high-risk human papillomavirus (HPV) infection. Persistent HPV infections can lead to cervical cancer in women, even though the majority of infections clear up on their own and have no symptoms. According to estimates by WHO, 145,700 women in the Western Pacific Region received a cervical cancer diagnosis in 2020, and 74,900 of them lost their lives to the most treatable and avoidable illness.

HPV Associated Disorders Diagnosis

• Vinegar (acetic acid) solution test, genital regions infected with HPV become white when a vinegar solution is administered to them. This test is useful in locating flat lesions that are hard to spot.
• Pap Test, for laboratory analysis, the doctor takes a sample of cells from your vagina or cervix. Pap testing can identify irregularities that may result in cancer.
• DNA Tests can identify the DNA of high-risk HPV strains that have been connected to genital malignancies using cells taken from the cervix. For women 30 years of age and above, it is advised in addition to the Pap test.

Market Key Developments

• In April 2023, a Phase 2 clinical study was initiated by KinoPharma, Inc. and IWAKI SEIYAKU CO., LTD. to verify the effectiveness of a therapeutic candidate for the treatment of cutaneous warts in humans.
• In December 2021, a one-year follow-up of safety and efficacy data in participants from REVEAL1, the completion of REVEAL2 enrollment, and the advancement of its pre-treatment biomarker candidate for VGX-3100 to be further developed with QIAGEN were among the updates on the Phase 3 programme for VGX-3100 for HPV-associated cervical high-grade squamous intraepithelial lesions (HSIL) that INOVIO released.

Segmentation:

By Indication

• CIN
• Cervical Cancer
• AIN
• Anal Cancer
• Others

By Therapy

• Prevention
• Treatment

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others